CDC variant reporthttps://covid.cdc.gov/covid-data-tracker/#variant-proportionsUploaded 19-09-22Some increase in BA.4.6 and BA.2.75BA.4.6 Progressive US increase, starting to slowly displace BA.5US of America (9,526)Canada (1,007)Denmark (500)France (400)Australia (288)Germany (248)Chile (242)Dominican Republic (173), Peru (149), Luxembourg (123), Belgium (102), Israel (101), Italy (94), Ireland (93), Sweden (92), Spain (85), Netherlands (84), Brazil (76), Argentina (68), Japan (67), New Zealand (60), Switzerland (54), Puerto Rico (53), South Africa (53), Ecuador (49), Mexico (35), Colombia (34), Trinidad and Tobago (30), Czech Republic (27), Costa Rica (23), Jamaica (21), Portugal (20), South Korea (19), Austria (17), Botswana (17), Indonesia (13), Sint Maarten (12), Senegal (11)BA.2.75Some US increaseGrowth rate is currently 61% per week relative to co-circulating lineages Current US nowcastBA.5 84.8% (UK, 87.2%)BA.4.6 10.3% (UK, 3.3)BA.4 1.8%BF.7 1.7%BA.2.75 1.3% (UK, 1.6%)BA.2 0% (UK, 0.5%)BA.1s 0%Delta 0%Others 0% (UK, 2.4%)XE 0%UK, technical briefing 45(September 2022) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103869/Technical-Briefing-45-9September2022.pdfContains early data and analysis on emerging variantsFindings have a high level of uncertaintyData cut-off of 5 September 2022BA.5 BA.5 is the predominant circulating variant in the United Kingdom Newly designated variant – V-22SEP-01 (BA.4.6) Omicron sub-lineage BA.4.6An apparent small growth advantage relative to BA.5. BA.4.6 represented 3.31% of UK samplesPreliminary neutralisation data from BA.4.6Expect some immune escape from BA.4 or BA.5 antibodiesThere is NO increased risk of hospital admission after BA.4 or BA.5 infection compared to BA.2 infection. Expect some immune escape triple dosed recipients of the Pfizer BNT162b2 vaccine. V-22JUL-01 (BA.2.75) As of 6 September 2022BA.2.75 in the UK, 1.6%Does seem to have growth advantage over co-circulating lineages of, 61% per weekTwo sub-lineages of BA.2.75 (BA.2.75.1 and BA.2.75.2) are currently being assessedBA.4/BA.5 Severity A case-control studyRisk of being admitted to hospital as an inpatientAmong people presenting to emergency care within 14 days of positive test. Comparison, risk of admission with BA.4 or BA.5 versus BA.2Between 16 March 2022 and 23 August 2022BA.4 n = 2,530BA.5 n = 12,026BA.2 n = 17,022Adjusted for age, sex, vaccination status, week of test, 2 days of extreme heatThere was no difference in the risk of admission between people infected with BA.4 compared to BA.2There was no difference in the risk of admission between people infected with BA.5 compared to BA.2 Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices
